Rockwell Medical, Inc. (NASDAQ:RMTI – Free Report) – Stock analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Rockwell Medical in a report released on Monday, March 24th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings of ($0.02) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $3.00 target price on the stock. The consensus estimate for Rockwell Medical’s current full-year earnings is $0.03 per share. HC Wainwright also issued estimates for Rockwell Medical’s Q2 2026 earnings at ($0.02) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at ($0.01) EPS and FY2026 earnings at ($0.06) EPS.
Separately, StockNews.com lowered Rockwell Medical from a “buy” rating to a “hold” rating in a research report on Friday, December 20th.
Rockwell Medical Stock Performance
Shares of NASDAQ:RMTI opened at $1.20 on Tuesday. The company has a current ratio of 2.41, a quick ratio of 2.00 and a debt-to-equity ratio of 0.33. Rockwell Medical has a 12 month low of $1.18 and a 12 month high of $5.15. The company has a market capitalization of $38.78 million, a price-to-earnings ratio of -24.00 and a beta of 1.55. The firm’s 50-day moving average is $1.82 and its 200 day moving average is $2.58.
Rockwell Medical (NASDAQ:RMTI – Get Free Report) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.04). Rockwell Medical had a negative net margin of 1.25% and a positive return on equity of 8.55%. The firm had revenue of $24.67 million for the quarter, compared to the consensus estimate of $23.65 million.
Institutional Trading of Rockwell Medical
A number of large investors have recently made changes to their positions in the stock. Raymond James Financial Inc. purchased a new position in Rockwell Medical in the 4th quarter worth about $28,000. Two Sigma Securities LLC bought a new position in Rockwell Medical in the 4th quarter worth about $33,000. Barclays PLC bought a new position in Rockwell Medical in the 3rd quarter worth about $90,000. XTX Topco Ltd increased its position in shares of Rockwell Medical by 45.7% during the third quarter. XTX Topco Ltd now owns 28,455 shares of the company’s stock worth $113,000 after acquiring an additional 8,922 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in shares of Rockwell Medical by 134,397.1% during the third quarter. JPMorgan Chase & Co. now owns 47,074 shares of the company’s stock valued at $187,000 after acquiring an additional 47,039 shares in the last quarter. 23.31% of the stock is owned by hedge funds and other institutional investors.
Rockwell Medical Company Profile
Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.
Recommended Stories
- Five stocks we like better than Rockwell Medical
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- Innovation Incubators: Survey of Entrepreneurs Reveals The Cities Most Supportive of Startups
- How to Invest in Blue Chip Stocks
- NVIDIA Insiders Sell: This Is What It Means for the Market
- Industrial Products Stocks Investing
- Space Stocks Bottoming: Which Are Positioned Best for a Bounce?
Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.
